PTEN hamartoma tumor syndromes

European Journal of Human Genetics

Volumn 16, Issue 11, 2008, Pages 1289-1300

  Blumenthal, Gideon M ^a   Dennis, Phillip A ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; CYCLOSPORIN; MAMMALIAN TARGET OF RAPAMYCIN; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; RAPAMYCIN;

ARTICLE; BANNAYAN RILEY RUVALCABA SYNDROME; BREAST CANCER; CANCER RISK; CANCER SCREENING; CANCER SURGERY; CANCER SUSCEPTIBILITY; CHROMOSOME 10Q; CLINICAL FEATURE; COMBINATION CHEMOTHERAPY; COWDEN SYNDROME; ENDOMETRIUM CANCER; GENE DELETION; GENE EXPRESSION REGULATION; GENE LOCATION; GENE LOSS; GENE MUTATION; GENETIC DISORDER; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; GERMLINE MUTATION; HAMARTOMA; HUMAN; LHERMITTE DUCLOS DISEASE; MULTIPLE CANCER; MUTATION; PRIORITY JOURNAL; PTEN HAMARTOMA TUMOR SYNDROME; THYROID CANCER; TUMOR SUPPRESSOR GENE;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ANTINEOPLASTIC AGENTS; CELL MOVEMENT; CELL PROLIFERATION; CELL SURVIVAL; CHROMOSOMES, HUMAN, PAIR 10; FEMALE; HAMARTOMA SYNDROME, MULTIPLE; HUMANS; MALE; MUTATION; PROTEIN KINASES; PROTO-ONCOGENE PROTEINS C-AKT; PTEN PHOSPHOHYDROLASE; SIGNAL TRANSDUCTION;

EID: 54549099013     PISSN: 10184813     EISSN: 14765438     Source Type: Journal    
DOI: 10.1038/ejhg.2008.162     Document Type: Article

References (77)

1. Eng C: Will the real Cowden syndrome pleaRe stand up: revised diagnostic criteria. J Med Genet 2000; 37: 828-830.
2. Marsh DJ, Coulon V, Lunetta KL et al: Mutation spectrum and genotype-phenotype analyses in Cowden disease and Bannayan-Zonana syndrome, two hamartoma syndromes with germline PTEN mutation. Hum Mol Genet 1998; 7: 507-515.
3. Ong C: PTEN: one gene, many syndromes. Hum Mutat 2003; 22: 183-198.
4. Tamura M, Gu J, Matsumoto K, Aota S, Parsons R, Yamada KM: Inhibition of cell migration, spreading, and focal adhesions by tumor suppressor PTEN. Science 1998; 280: 1614-1617.
5. Limpson L, Parsons R: PTEN: life as a tumor suppressor. Exp Cell Res 2001; 264: 29-41.
6. Weng LP, Smith WM, Brown JL, Eng C: PTEN inhibits insulin-stimulated MEK/ MAPK activation and cell growth by blocking IRS-1 phosphorylation and IRS-1/Grb-2/Sos complex formation in a breast cancer model. Hum Mol Genet 2001; 10: 605-616.
7. Shen WH, Balajee AS, Wang J et al: Essential role for nuclear PTEN in maintaining chromosomal integrity. Cell 2007; 128: 157-170.
8. Di Cristofano A, Pesce B, Cordon-Cardo C, Pandolfi PP: Pten is essential for embryonic development and tumour suppression. Nat Genet 1998; 19: 348-355.
9. Suzuki A, de la Pompa JL, Stambolic V et al: High cancer susceptibility and embryonic lethality associated with mutation of the PTEN tumor suppressor gene in mice. Curr Biol 1998; 8: 1169-1178.
10. Podsypanina K, Ellenson LH, Nemes A et al: Mutation of Pten/Mmac1 in mice causes neoplasia in multiple organ systems. Proc Natl Acad Sci USA 1999; 96: 1563-1568.
11. Furnari FB, Lin H, Huang HS, Cavenee WK: Growth suppression of glioma cells by PTEN requires a functional phosphatase catalytic domain. Proc Natl Acad Sci USA 1997; 94: 12479-12484.
12. Davies MA, Kim SJ, Parikh NU, Dong Z, Bucana CD, Gallick GE: Adenoviral-mediated expression of MMAC/PTEN inhibits proliferation and metastasis of human prostate cancer cells. Clin Cancer Res 2002; 8: 1904-1914.
13. Stainbolic V, Suzuki A, de la Pompa JL et al: Negative regulation of PKB/Akt-dependent cell survival by the tumor suppressor PTEN. Cell 1998; 95: 29-39.
14. Lloyd II KM, Dennis M: Cowden's disease. A possible new symptom complex with multiple system involvement. Ann Intern Med 1963; 58: 136-142.
15. Liaw D, Marsh DJ, Li J et al: Germline mutations of the PTEN gene in Cowden disease, an inherited breast and thyroid cancer syndrome. Nat Genet 1997; 16: 64-67.
16. Starink TM, van der Veen JP, Arwert F et al: The Cowden syndrome: a clinical and genetic study in 21 patients. Clin Genet 1986; 29: 222-233.
17. McGarrity TJ, Wagner Baker MJ, Ruggiero FM et al: GI polyposis and glycogenic acanthosis of the esophagus associated with PTEN mutation positive Cowden syndrome in the absence of cutaneous manifestations. Am J Gastroenterol 2003; 98: 1429-1434.
18. Harach HR, Soubeyran I, Brown A, Bonneau D, Longy M: Thyroid pathologic findings in patients with Cowden disease. Ann Diagn Pathol 1999; 3: 331-340.
19. Schrager CA, Schneider D, Gruener AC, Tsou HC, Peacocke M: Clinical and pathological features of breast disease in Cowden's syndrome: An underrecognized syndrome with an increased risk of breast cancer. Hum Pathol 1998; 29: 47-53.
20. Gustafson S, Zbuk KM, Scacheri C, Eng C: Cowden syndrome. Semin Oncol 2007; 34: 428-434.
21. Tan WH, Baris HN, Burrows PE et al: The spectrum of vascular anomalies in patients with PTEN mutations: Implications for diagnosis and management. J Med Genet 2007; 44: 594-602.
22. Lachlan KL, Lucassen AM, Bunyan D, Temple IK: Cowden syndrome and Bannayan Riley Ruvalcaba syndrome represent one condition with variable expression and age-related penetrance: Results of a clinical study of PTEN mutation carriers. J Med Genet 2007; 44: 579-585.
23. Longy M, Lacombe D: Cowden disease. Report of a family and review. Ann Genet 1996; 39: 35-42.
24. Nusbaum R, Vogel KJ, Ready K: Susceptibility to breast cancer: hereditary syndromes and low penetrance genes. Breast Dis 2006; 27: 21-50.
25. Fackenthal JD, Marsh DJ, Richardson AL et al: Male breast cancer in Cowden syndrome patients with germline PTEN mutations. J Med Genet 2001; 38: 159-164.
26. Pilarski R, Eng C: WIll the real Cowden syndrome please stand up (again)? Expanding mutational and clinical spectra of the PTEN hamartoma tumour syndrome. J Med Genet 2004; 41: 323-326.
27. Marsh DJ, Kum JB, Lunetta KL et al: PTEN mutation spectrum and genotype-phenotype correlations in Bannayan-Riley-Ruvalcaba syndrome suggest a single entity with Cowden syndrome. Hum Mol Genet 1999; 8: 1461-1472.
28. Zhou XP, Waite KA, Pilarski R et al: Germline PTEN promoter mutations and deletions in Cowden/Bannayan-Riley-Ruvalcaba syndrome result in aberrant PTEN protein and dysregulation of the phosphoinositol-3-kinase/Akt pathway. Am J Hum Genet 2003; 73 404-411.
29. Yang H, Kong W, He L et al: MicroRNA expression profiling in human ovarian cancer: MiR-214 induces cell survival and cisplatin resistance by targeting PTEN. Cancer Res 2008; 68: 425-433.
30. Trotman LC, Wang X, Alimonti A et al: Ubiquitination regulates PTEN nuclear import and tumor suppression. Cell 2007; 128: 141-156.
31. Wang X, Trotman LC, Koppie T et al: NEDD4-1 is a protooncogenic ubiquitin ligase for PTEN. Cell 2007; 128: 129-139.
32. Mirmohammadsadegh A, Marini A, Nambiar S et al: Epigenetic silencing of the PTEN gene in melanoma. Cancer Res 2006; 66: 6546-6552.
33. Sarquis MS, Agrawal S, Shen L, Pilarski R, Zhou XP, Eng C: Distinct expression profiles for PTEN transcript and its splice variants in Cowden syndrome and Bannayan-Rdey-Ruvalcaba syndrome. Am J Hum Genet 2006; 79: 23-30.
34. Agrawal S, Eng C: Differential expression of novel naturally occurring splice variants of PTEN and their functional consequences in Cowden syndrome and sporadic breast cancer. Hum Mol Genet 2006; 15: 777-787.
35. Zbuk KM, Eng C: Cancer phenomics: REr and PTEN as illustrative models. Nat Rev Cancer 2007; 7: 35-45.
36. Zhou XP. Marsh DJ, Morrison CD et al: Germline inactivation of PTEN and dysregulation of the phosphoinositol-3-kinase/Akt pathway cause human Lhermitte-Duclos disease in adults. Am J Hum Genet 2003; 73: 1191-1198.
37. Williams III DW, Elster AD, Ginsberg LE, Stanton C: Recurrent Lhermitte-Duclos disease: Report of two cases and association with Cowden's disease. AJNR Am J Neuroradiol 1992; 13: 287-290.
38. Abel TW, Baker SJ, FAaser MM et al: Lhermitte-Duclos disease: a report of 31 cases with immunohistochemical analysis of the PTEN/AKT/ mTOR pathway. J Neuropathol Exp Neurol 2005; 64: 341-349.
39. Bannayan GA: Lipomatosis, angiomatosis, and macrencephalia. A previously undescribed congenital syndrome. Arch Pathol 1971; 92: 1-5.
40. Moretti-Ferreira D, Koiffmann CP, Souza DH, Diament AJ, Wajntal A: Macrocephaly, multiple lipomas, and hemangiomata (Bannayan-Zonana syndrome): Genetic heterogeneity or autosomal dominant locus with at least two different allelic forms? Am J Med Genet 1989; 34: 548-551.
41. Miles JH, Zonana J, McFarlane J, Aleck KA, Bawle E: Macrocephaly with hamartomas: Bannayan-Zonana syndrome. Am J Med Genet 1984; 19 225-234.
42. Hayashi Y, Ohi R, Tomita Y, Chiba T, Matsumoto Y: Bannayan-Zonana syndrome associated with lipomas, hemangiomas, and lymphangiomas. J Pediatr Surg 1992; 27: 722-723.
43. Parisi MA, Dinulos MB, Leppig KA, Sybert VP, Eng C, Hudgins L: The spectrum and evolution of phenotypic findings in PTEN mutation positive cases of Bannayan-Riley-Ruvalcaba syndrome. J Med Genet 2001; 38: 52-58.
44. Wiedemann HR, Burgio GR, Aldenhoff P, Kunze J, Kaufmann HJ, Schirg E: The proteus syndrome. Partial gigantism of the hands and/or feet, nevi, hemihypertrophy, subcutaneous tumors, macrocephaly or other skull anomalies and possible accelerated growth and visceral affections. Eur J Pediatr 1983; 140: 5-12.
45. Cohen MM, JrA Proteus syndrome: an update. Am J Med Genet C Semin Med Genet 2005; 137: 38-52.
46. Cohen Jr MM,MTurner JT. Biesecker LG: Proteus syndrome: misdiagnosis with PTEN mutations. Am J Med Genet A 2003; 122: 323-324.
47. Zhou X, Hampel H, Thiele H et al: Association of germline mutation in the PTEN tumour suppressor gene and Proteus and Proteus-like syndromes. Lancet 2001; 358: 210-211.
48. Smith JM, Kirk EP. Theodosopoulos G et al: Germline mutation of the tumour suppressor PTEN in Proteus syndrome. J Med Genet 2002; 39: 937-940.
49. Biesecker LG, Rosenberg MJ, Vacha S, Turner JT, Cohen MM: PTEN mutations and proteus syndrome. Lancet, 2001; 358: 2079-2080.
50. Thiffault I, Schwartz CE, Der Kaloustian V, Foulkes WD: Mutation analysis of the tumor suppressor PTEN and the glypican 3 (GPC3) gene in patients diagnosed with Proteus; syndrome. Am J Med Genet A 2004; 130: 123-127.
51. Happle R: Type 2 segmental Cowden disease vs Proteus syndrome. Br J Dermatol 2007; 156: 1089-1090.
52. Happle R: LineaA Cowden nevus: a new distinct epidermal nevus. Eur J Dermatol 2007; 17: 133-136.
53. Caux F, Plauchu H, Chibon F et al: Segmental overgrowth, lipomatosis, arteriovenous malformation and epidermal nevus (SOLAMEN) syndrome is related to mosaic PTEN nullizygosity. Eur J Hum Genet 2007; 15: 767-773.
54. Buxbaum JD, Cai G, Chaste P et al: Mutation screening of the PTEN gene in patients with autism spectrum disorders and macrocephaly. Am J Med Genet B Netappsychiatr Genet 2007; 144: 484-491.
55. Reardon W, Zhou XP, Eng C: A novel germline mutation of the PTEN gene in a patient with macrocephaly, ventricular dilatation, and features of VATER association. J Med Genet 2001; 38: 820-823.
56. Sweet K, Willis J, Zhou XP et al: Molecular classification of patients with unexplained hamartomatous and hyperplastic polyposis. JAMA 2005; 294: 2465-2473.
57. van Hattem WA, Brosens; LA, de Leng WW et al: Large genomic deletions of Smad4, Bmpr1a and Pten in juvenile polyposis. Gut 2008; 57 (5): 623-627.
58. Meijers-Heijboer H, van Geel B, van Putten WL et al: Breast cancer after prophylactic bilateral mastectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med 2001; 345: 159-164.
59. Hartmann LC, Sellers TA, Schaid DJ et al: Efficacy of bilateral prophylactic mastectomy in BRCA1 and BRCA2 gene mutation carriers. J Natl Cancer Inst 2001; 93: 1633-1637.
60. Fisher B, Costantino JP, Wickerham DL et al: Tamoxifen for the prevention of breast cancer: Current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst 2005; 97: 1652-1662.
61. Vogel VG, Costantino JP, Wickerham DL et al: Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: The NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA 2006; 295: 2727-2741.
62. Shi Y, Gera J, Hu L et al: Enhanced sensitivity of multiple myeloma cells containing PTEN mutations to CCI-779. Cancer Res 2002; 62: 5027-5034.
63. Neshat MS, Mellinghoff IK, Tran C et al: Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR. Proc Natl Acad Sci USA 2001; 98: 10314-10319.
64. Yu K, Toral-Barza L, Discafani C et al: MTOR, a novel target in breast cancer: The effect of CCI-779, an mTOR inhibitor, in preclinical models of breast cancer. Endocr Relat Cancer 2001; 8: 249-258.
65. +/- mice. Proc Natl Acad Sci USA 2001; 98: 10320-10325.
66. Bissler JJ, McCormack FX, Young IR et al: Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangio-leiomyomatosis. N Engi J Med 2008; 358: 140-151.
67. Marsh DJ, Trahair TN, Martin JL et al: Rapamycin treatment for a child with germline PTEN mutation. Nat Clin Pract Oncol 2008; 5 357-361.
68. Fujio Y, Nguyen T, Wencker D, Kitsis RN, Walsh K: Akt promotes survival of cardiomyocytes in vitro and protects against ischemia-reperfusion injury in mouse heart. Circulation 2000; 101: 660-667.
69. Zdychova J, Komers R: Emerging role of Akt kinase/protein kinase B signaling in pathophysiology of diabetes and its complications. Physiol Res 2005; 54: 1-16.
70. Sun SY, Rosenberg LM, Wang X et al: Activation of Akt and eIF4E survival pathways by rapamycin-mediated mammalian target of rapamycin inhibition. Cancer Res 2005; 65: 7052-7058.
71. O'Reilly KE, Rojo F, She QB et al: MTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res 2006; 66: 1500-1508.
72. Wan X, Harkavy B, Shen N, Grohar P, Heiman LJ: Rapamycin induces feedback activation of Akt signaling through an IGF-1R-dependent mechanism. Oncogene 2007; 26: 1932-1940.
73. Cloughesy TF, Yoshimoto K, Nghiemphu P et al: Antitumor activity of rapamycin in a phase I trial for patients with recurrent PTEN-deficient glioblastoma. PLoS Med 2008, 5: E8.
74. Fan QW, Cheng CK, Nicolaides TP et al: A dual phosphoinositide-3-kinase alpha/mTOR inhibitor cooperates with blockade of epidermal growth factor receptor in PTEN-mutant glioma. Cancer Res 2007; 67: 7960-7965.
75. Papadopoulos KP, Markman B, Tabernero J et al: A phase I dose-escalation study of the safety, parmacokinetics (PK), and pharmacodynamics (PD) of a novel PI3K inhibitor, XL765, administered orally to patients (pts) with advanced solid tumors. J Clin Oncol 2008; 26: (20 May suppl; abstract 3510).
76. Beilina A, Van Der Brug M, Ahmad R et al: Mutations in PTEN-induced putative kinase 1 associated with recessive parkinsonism have differential effects on protein stability. Proc Natl Acad Sci USA 2005; 102: 5703-5708.
77. Unoki M, Nakamura Y: Growth-suppressive effects of BPOZ and EGR2, two genes involved in the PTEN signaling pathway. Oncogene 2001; 20 4457-4465.